- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …practices.Develop positive relationships with the QA team, Quality Control, Information Technology , maintenance, Manufacturing personnel, Technical Operations ... we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …instructions.Develop positive relationship with the QA team, Quality Control, Information Technology , Maintenance, Manufacturing personnel, Technical Operations ... we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and...knowledge of the employees in the maintenance process, the information from SAP, the technical documentation and other data… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and...to complete tasks, knows how to get resources and information from established internal contacts; consult with supervisor for… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and...to complete tasks, knows how to get resources and information from established internal contacts; escalates to management when… more
- Legend Biotech USA, Inc. (Piscataway, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Piscataway, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and commercialize ciltacabtagene… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and ... agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson , to jointly develop and...procedures and batch records, while recording production data and information in a clear, concise format.Perform tasks on time… more
